13 January 2011

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO US PERSONS

IMPEDI MED EXTENDS SPP CLOSING DATE TO MONDAY 24 JANUARY 2011

Brisbane, Australia. – ImpediMed Limited (“ImpediMed” or “Company”) refers to its announcements in December 2010 regarding the Company’s Share Purchase Plan (“SPP”) which is due to close on Monday 17 January 2011.

Due to the extensive flooding experienced in Brisbane and other parts of Eastern Australia, the ImpediMed Board has today decided to extend the closing date of the SPP by one week to Monday 24 January 2011 to allow eligible shareholders that wish to participate in the SPP additional time to submit their applications.

Eligible shareholders that wish to participate in the SPP are encouraged to submit their application via BPAY® to ensure it is received before the closing date.

If you have lost your SPP offer document or application form and wish to participate in the SPP, please call Link Market Services Limited on 1800 500 095 (callers within Australia) or +61 2 8280 7208 (callers outside Australia) to arrange for these documents to be provided to you.

The revised timetable for the SPP is set out below.*

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPP offer closes</td>
<td>24 January 2011</td>
</tr>
<tr>
<td>Issue of shares under the SPP</td>
<td>28 January 2011</td>
</tr>
<tr>
<td>Expected date for commencement of trading</td>
<td>31 January 2011</td>
</tr>
<tr>
<td>of shares issued under the SPP</td>
<td></td>
</tr>
</tbody>
</table>

* These dates are indicative only and ImpediMed reserves the right to vary the timetable if necessary.
Information on the SPP

The SPP is open to all holders of ImpediMed shares with a registered address in Australia and New Zealand as at 7.00 pm (Sydney time) on 2 December 2010 ("Eligible Shareholders"). Eligible Shareholders can subscribe for up to A$15,000 in ImpediMed shares per Eligible Shareholder at the offer price of A$0.70 per share. ImpediMed reserves the right to scale back applications under the SPP, at its discretion, if total demand exceeds A$5.0 million. The SPP is underwritten up to a maximum of A$4.27 million by Wilson HTM and RBS Morgans.

Enquiries about the SPP should be directed to ImpediMed’s CEO, Greg Brown, on +61 7 3860 3700.

ENDS

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and may not be distributed or released in the United States. This announcement does not constitute an offer of shares for sale in the United States or in any other jurisdiction in which such an offer would be illegal. The new shares the subject of the SPP have not been, and will not be, registered under the US Securities Act of 1933 and, accordingly, may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of such Act and applicable US state securities laws.

The securities to be issued under the SPP have not been, and will not be, registered under the US Securities Act of 1933. Securities may not be offered or sold in the United States or to US persons unless the securities have been registered under the Securities Act or an exemption from registration is available.